Ozempic is FDA-approved for adults with type 2 diabetes, and its label carries real, specific risks. The answer depends on who is taking it and why. The numbers below come from the current US prescribing information, dated June 2026 [1]. For what Ozempic is, see our Ozempic guide.
Ozempic is approved for type 2 diabetes and two of its complications
The label gives Ozempic three uses, all in adults with type 2 diabetes [1]:
- To improve blood sugar, along with diet and exercise.
- To lower the risk of heart attack, stroke and heart-related death in people who also have heart disease.
- To lower the risk of kidney decline, kidney failure and heart-related death in people who also have chronic kidney disease.
That's the whole list. Weight loss isn't on it. The semaglutide brand approved for weight is Wegovy, which has its own label and dose range; see our Wegovy guide.
Digestive effects are common; individual symptoms have different rates
The label's main table pools two placebo-controlled trials in people with type 2 diabetes, about 260 people per group, for an average of 33 weeks on Ozempic [1]. About one person in three on Ozempic had a digestive side effect: 32.7% at 0.5 mg and 36.4% at 1 mg, against 15.3% on placebo.
| Side effect | Placebo | Ozempic 0.5 mg | Ozempic 1 mg |
|---|---|---|---|
| Nausea | 6.1 | 15.8 | 20.3 |
| Vomiting | 2.3 | 5.0 | 9.2 |
| Diarrhea | 1.9 | 8.5 | 8.8 |
| Abdominal pain | 4.6 | 7.3 | 5.7 |
| Constipation | 1.5 | 5.0 | 3.1 |
| Indigestion (dyspepsia) | 1.9 | 3.5 | 2.7 |
| Burping (eructation) | 0 | 2.7 | 1.1 |
| Heartburn and reflux (GERD) | 0 | 1.9 | 1.5 |
| Gas (flatulence) | 0.8 | 0.4 | 1.5 |
| Gastritis | 0.8 | 0.8 | 0.4 |
| Any digestive side effect | 15.3 | 32.7 | 36.4 |
Ozempic prescribing information, DailyMed version 20, June 2026, Table 1 and §6.1. The label also lists fatigue, taste changes (dysgeusia) and dizziness at more than 0.4%, and injection-site reactions in 0.2%.
Low blood sugar depends mostly on what else you take. On Ozempic alone, severe episodes were 0% in the label's monotherapy trial. With a sulfonylurea, severe low blood sugar reached 0.8% at 0.5 mg and 1.2% at 1 mg [1]. If you use insulin or a sulfonylurea, your prescriber may lower that dose when Ozempic starts.
Other side effects have their own pages: bruising, itching and rash, thirst, urination and dry mouth, and the facial changes people call "Ozempic face".
Most nausea, vomiting and diarrhea came while the dose was rising
The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation.[1]
Ozempic starts at 0.25 mg a week and allows up to 2 mg; the label says that slow start is there "to reduce the risk of gastrointestinal adverse reactions" [1]. Your prescriber decides the dose steps. In the trials, 3.1% at 0.5 mg and 3.8% at 1 mg stopped because of digestive side effects, against 0.4% on placebo. For each stomach symptom in detail, see Ozempic's stomach side effects.
The label’s warnings include risks with uncertain frequencies
| Risk | How often (label) | Signs the label lists | Section |
|---|---|---|---|
| Thyroid C-cell tumors | Seen in rodents; unknown in people | Lump or swelling in the neck, hoarseness, trouble swallowing, shortness of breath | Boxed, 5.1 |
| Acute pancreatitis | 0.3 vs 0.2 cases per 100 patient-years (vs comparators) | Severe stomach pain that won't go away, sometimes into the back, with or without vomiting | 5.2 |
| Eye complications (diabetic retinopathy) | 3.0% vs 1.8% over 2 years; 8.2% vs 5.2% with prior retinopathy | Changes in vision | 5.3 |
| Low blood sugar with insulin or a sulfonylurea | Severe: 0.8 to 1.2% with a sulfonylurea | Shakiness, sweating, confusion, fast heartbeat | 5.5 |
| Kidney injury from dehydration | Postmarketing reports, some needing dialysis | Follows vomiting, diarrhea or nausea that doesn't stop | 5.6 |
| Severe digestive reactions | 0.4% (0.5 mg) and 0.8% (1 mg) vs 0% | Stomach problems that are severe or won't go away | 5.7 |
| Serious allergic reactions | Reported; rate not given | Swelling of face, lips, tongue or throat; trouble breathing; severe rash; very fast heartbeat | 5.8 |
| Gallstones | 1.5% (0.5 mg) and 0.4% (1 mg) vs 0% | Upper belly pain, fever, yellow skin or eyes, clay-colored stools | 5.9 |
| Food in the lungs under anesthesia | Rare postmarketing reports | Tell the surgical team you take Ozempic | 5.10 |
| Pen sharing | Not a rate; a rule | Never share a pen, even with a new needle | 5.4 |
Ozempic prescribing information, DailyMed version 20, June 2026. The label also says Ozempic is not recommended for people with severe gastroparesis (§5.7).
The boxed warning is the one people ask about. In mice and rats, semaglutide caused thyroid C-cell tumors; the label says it is "unknown" whether Ozempic does this in people [1]. The human evidence is in semaglutide and thyroid cancer. It discusses semaglutide evidence relevant to this warning; the products’ doses, populations and indications still differ.
Postmarketing reports also include ileus, intestinal obstruction and severe constipation with fecal impaction. Voluntary reports cannot reliably establish frequency or causation [1]. Severe persistent pain, vomiting or inability to keep fluids down needs prompt clinical assessment; do not dismiss it because common nausea occurred during escalation. Before surgery or deep sedation, tell the anesthesia team about Ozempic. The label says data are insufficient to establish whether temporarily stopping it or changing fasting recommendations reduces aspiration risk.
SUSTAIN 6 found fewer major heart events in high-risk diabetes
Two large trials on the label measured hard outcomes, not just blood sugar. Both were funded by Novo Nordisk, which makes Ozempic [2] [3].
| Trial | Who | Follow-up | Result | Safety note |
|---|---|---|---|---|
| SUSTAIN 6 | 3,297 adults with type 2 diabetes and high cardiovascular risk; 83% had cardiovascular disease, kidney disease or both | Median 2.1 years | Heart attack, stroke or heart death: 6.6% vs 8.9%; HR 0.74 (95% CI 0.58–0.95) | More diabetic eye complications (3.0% vs 1.8%) |
| FLOW | 3,533 adults with type 2 diabetes and chronic kidney disease | Median 41 months | Kidney composite or kidney/cardiovascular death: 18.7% vs 23.2%; HR 0.76 (95% CI 0.66–0.88) | No new serious adverse reactions identified |
Ozempic prescribing information §14.2 Table 9 and §14.3 Table 10, June 2026. A hazard ratio of 0.74 describes 26% lower relative hazard, not 26 percentage points fewer patients. Trial population and outcome definitions matter.
In SUSTAIN 6, non-fatal strokes were also lower (1.6% vs 2.7%). The eye signal came from the same trial, so both findings belong in the discussion. They do not mean every individual who benefits will develop eye complications, or that the overall trial result establishes a benefit-risk decision for every patient [1].
The label rules Ozempic out for two groups and urges caution for several more
- Do not use with a personal or family history of medullary thyroid carcinoma, or with MEN 2.
- Do not use after a serious allergic reaction to semaglutide or any ingredient in Ozempic.
- Not recommended with severe gastroparesis (very slow stomach emptying).
- Pregnancy: stop at least 2 months before a planned pregnancy, because semaglutide takes a long time to leave the body.
- Tell your prescriber about past pancreas problems, diabetic retinopathy, kidney disease, or a history of anaphylaxis or angioedema with another GLP-1 drug.
The first two are contraindications in §4. The rest come from §5, §8.3 and the Medication Guide [1].
Ozempic isn't approved for weight loss, so its label data come from people with diabetes
Some people are prescribed Ozempic off-label for weight. Its label can't tell you how safe that is, because every trial on it enrolled people with type 2 diabetes. Semaglutide for weight has been studied as Wegovy, at higher doses, with its own side-effect tables. See is Wegovy safe? for that evidence.
Compounded semaglutide sold for weight is a third thing again: it is not FDA-approved and does not undergo FDA premarket review for safety, effectiveness or quality [5]. See is compounded semaglutide safe?
The longest data on the label run about two to three and a half years
SUSTAIN 6 followed people for a median of 2.1 years and FLOW for a median of 41 months [1]. Those are follow-up periods for the two cited outcomes trials, not proof that no longer or different semaglutide study exists. Observational evidence has its own confounding limits. Stopping has its own effects: in an exploratory 327-person extension after semaglutide 2.4 mg and structured lifestyle support both stopped, participants regained about two-thirds of their prior loss over a year [4]. If you plan to stay on Ozempic for many years, that is a fair question to raise with your prescriber.
Tell your prescriber about thyroid, pancreas, gallbladder, kidney and eye history
The Medication Guide asks you to mention pancreas problems, diabetic retinopathy, severe stomach problems such as gastroparesis, planned surgery or sedation, and pregnancy or breastfeeding plans. List every medicine you take, including insulin, sulfonylureas, vitamins and supplements, because Ozempic slows stomach emptying and may affect how other pills are absorbed [1].
Cost is a separate decision. See does Medicare cover Ozempic? and what Ozempic costs without insurance. For the pill form of semaglutide, see oral semaglutide.